HOW IT WORKS
Making matches on the molecular level
The one-size-fits-all approach to mental health treatment works for no one. IDgenetix is a comprehensive pharmacogenomics (PGx) test that provides personalized medication profiles, tailored to a patient’s unique DNA. The test accounts for more factors that can influence a patient’s response to medication than any other PGx test.
PGx testing helps to determine a person’s metabolic phenotype – how their genes will impact their metabolism of drugs. Some people have genes that cause them to metabolize medicine very rapidly. Individuals with gene mutations associated with rapid metabolism may require higher doses of a medicine for it to have the same effect as someone with a lower metabolism. They may also experience fewer side effects.
Precision Prescribing for Personalized Patient Care in
Internal Medicine & Family Practice
Using one-size-fits-all medications often falls short of achieving desired outcomes. Mira Precision PGx delivers a comprehensive, personalized medication profile across 13 therapeutic areas, tailored to each patient’s unique DNA. Unlike tests focused solely on mental health, this advanced PGx test considers more factors influencing medication response than any other available—bringing improved accuracy, reduced adverse drug reactions, and cost-effective care to every patient.
- Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423-431.
- Yuan, J., et al. Preemptive Pharmacogenomic Testing for Precision Medicine. J Mol Diag. 2016;18(3):438-445.
- U.S. Food & Drug Administration. Table of Pharmacogenetic Associations FDA.gov.
- Mayo Clinic Proceedings. (2015). Clinical Implementation of Cardiovascular Pharmacogenomics. Mayo Clinic Proceedings.
- Schildcrout J.S., Denny J.C., Bowton E., et al. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clin Pharmacol Ther. 2012;92:235–242. doi: 10.1038/clpt.2012.66.
- Kimpton J., Carey I.M., Threapleton C.J., et al. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Pharmacol. 2019;85:2734–2746. doi: 10.1111/bcp.14100.
- Bradley, P., et al. (2018). Effectiveness of Pharmacogenomic Testing for the Treatment of Major Depressive Disorder in a Primary Care Setting. Journal of Psychiatric Research.
- National Institutes of Health (NIH). Pharmacogenomics: Precision Medicine and Patient Outcomes. NIH.gov.
- Bentley, T. G., et al. (2017). Cost-Effectiveness of Pharmacogenomic Testing in Patients with Chronic Pain and Cardiovascular Disease. Health Economic
Unlock the Power of Mira Precision PGx
PGx testing reveals a person’s metabolic phenotype, showing how their genes affect drug metabolism. Some individuals metabolize medications rapidly due to specific genetic variations, requiring higher doses for effectiveness and fewer side effects. Mira Precision PGx ensures that each patient receives the most suitable treatment, tailored precisely to their genetic makeup, whether it’s for oncology, cardiology, psychiatry, neurology, gastroenterology, endocrinology, rheumatology, respiratory, infectious diseases, pain management, urology, dermatology, or hematology.
Drug-Gene Interaction
Drug-Drug Interactions
Lifestyle factors & Environment
Integrating Mira Precision PGx into Long-Term
Care (LTC) Facilities
